TCR2 Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TCRR research report →
Companywww.tcr2.com
TCR2 Therapeutics Inc. , a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.
- CEO
- Garry E. Menzel
- IPO
- 2019
- Employees
- 58
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $58.11M
- P/E
- -0.38
- P/S
- 0.00
- P/B
- 0.41
- EV/EBITDA
- -0.88
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -71.90%
- ROIC
- -78.87%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-151,822,000 · -52.12%
- EPS
- $-3.93 · -49.43%
- Op Income
- $-153,499,000
- FCF YoY
- -25.64%
Performance & Tape
- 52W High
- $3.88
- 52W Low
- $0.82
- 50D MA
- $1.69
- 200D MA
- $1.56
- Beta
- 1.93
- Avg Volume
- 325.04K
Get TickerSpark's AI analysis on TCRR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 1, 23 | TANG KEVIN C | other | 4,394,800 |
| Jun 1, 23 | UBS Oncology Impact Fund L.P. | other | 3,370,982 |
| Jun 1, 23 | MPM SunStates Fund, L.P. | other | 4,158,964 |
| Jun 1, 23 | MPM BioVentures 2014, L.P. | other | 4,158,964 |
| Jun 1, 23 | GADICKE ANSBERT | other | 3,370,982 |
| Jun 1, 23 | Allen Andrew R | sell | 5,000 |
| Jun 1, 23 | Allen Andrew R | sell | 12,100 |
| Jun 1, 23 | Allen Andrew R | sell | 12,100 |
| Jun 1, 23 | Allen Andrew R | sell | 16,800 |
| Jun 1, 23 | Allen Andrew R | sell | 8,072 |
Our TCRR Coverage
We haven't published any research on TCRR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TCRR Report →